Birdwatch Note
2025-07-06 17:12:36 UTC - MISINFORMED_OR_POTENTIALLY_MISLEADING
Michael Yeadon was *a* VP at Pfizer, not *the* VP. He was middle-management. Pfizer has over 1,400 staff at the VP level www.LinkedIn.com Yeadon managed a small team of 40 developing a product that he eventually sold to Novartis, but it failed trials causing a writedown of $485 million. https://www.reuters.com/investigates/special-report/health-coronavirus-vaccines-skeptic/
Written by 50370F2CC1A8443BE26AA05557B340BCB77C4882D0799A8FCFC741BD6D61390C
Participant Details
Original Tweet
Tweet embedding is no longer reliably available, due to the platform's instability (in terms of both technology and policy). If the Tweet still exists, you can view it here: https://twitter.com/foo_bar/status/1941318590562746629
Please note, though, that you may need to have your own Twitter account to access that page. I am currently exploring options for archiving Tweet data in a post-API context.
All Information
- ID - 1941908147800518832
- noteId - 1941908147800518832
- participantId -
- noteAuthorParticipantId - 50370F2CC1A8443BE26AA05557B340BCB77C4882D0799A8FCFC741BD6D61390C Participant Details
- createdAtMillis - 1751821956002
- tweetId - 1941318590562746629
- classification - MISINFORMED_OR_POTENTIALLY_MISLEADING
- believable -
- harmful -
- validationDifficulty -
- misleadingOther - 0
- misleadingFactualError - 1
- misleadingManipulatedMedia - 0
- misleadingOutdatedInformation - 0
- misleadingMissingImportantContext - 1
- misleadingUnverifiedClaimAsFact - 1
- misleadingSatire - 0
- notMisleadingOther - 0
- notMisleadingFactuallyCorrect - 0
- notMisleadingOutdatedButNotWhenWritten - 0
- notMisleadingClearlySatire - 0
- notMisleadingPersonalOpinion - 0
- trustworthySources - 1
- summary
- Michael Yeadon was *a* VP at Pfizer, not *the* VP. He was middle-management. Pfizer has over 1,400 staff at the VP level www.LinkedIn.com Yeadon managed a small team of 40 developing a product that he eventually sold to Novartis, but it failed trials causing a writedown of $485 million. https://www.reuters.com/investigates/special-report/health-coronavirus-vaccines-skeptic/
Note Ratings
| rated at | rated by | |
| 2025-07-06 14:15:43 -0400 | Rating Details | |
| 2025-07-06 14:30:42 -0400 | Rating Details | |
| 2025-07-06 14:14:18 -0400 | Rating Details | |
| 2025-07-06 13:45:25 -0400 | Rating Details | |
| 2025-07-07 22:23:23 -0400 | Rating Details | |
| 2025-07-07 17:55:04 -0400 | Rating Details | |
| 2025-07-07 17:13:39 -0400 | Rating Details | |
| 2025-07-07 17:15:13 -0400 | Rating Details | |
| 2025-07-08 08:09:16 -0400 | Rating Details | |
| 2025-07-19 10:33:33 -0400 | Rating Details |